Multitargeted Synergistic Mechanisms of Salvia miltiorrhiza and Its Bioactive Compounds: A Review.
Salvia miltiorrhiza Bunge (S. miltiorrhiza) is a traditional Chinese medicinal herb highly valued both locally and globally for its ability to improve blood circulation, resolve blood stasis, nourish heart blood, alleviate hernia pain, calm the mind, and support tumor treatment. Recently, extensive research has explored the potential of S. miltiorrhiza and its active compounds in treating cardiovascular diseases, neurodegenerative disorders, and cancer.
This review aims to elucidate the synergistic effects of S. miltiorrhiza and its bioactive constituents across various stages of cardiovascular diseases, neurodegenerative disorders, and cancer progression by summarizing the key targets and signaling pathways involved.
A comprehensive search was conducted across PubMed, Web of Science, EMBASE, the Cochrane Library, SpringerLink, Elsevier, and the China National Knowledge Infrastructure (CNKI). The keywords employed included "cardiovascular protection", "neuroprotection", "anti-cancer", "Salvia miltiorrhiza", "active ingredients", and "pharmacological mechanisms". Relevant studies published from 2010 to 2025 were systematically screened, extracted, and analyzed to elucidate the mechanistic pathways and translational potential of S. miltiorrhiza and its active constituents in various therapeutic contexts. Furthermore, authoritative materials, monographs, and classical texts published prior to 2010 were referenced to provide historical and ethnopharmacological context.
S. miltiorrhiza's active constituents exert synergistic, multi-target regulation of oxidative stress, inflammation, and cell death across cardiovascular, cerebrovascular, and oncological diseases, embodying the modern connotation of "treating different diseases with the same method." Pharmacokinetically, lipophilic constituents exhibit extensive tissue distribution but low oral bioavailability, whereas hydrophilic constituents show the opposite; their combination may optimize in vivo exposure and therapeutic effects. Mechanistically, S. miltiorrhiza combats atherosclerosis by modulating cholesterol metabolism, inflammation, and vascular function; ameliorates neuronal damage by interfering with Aβ metabolism and neurotransmitter signaling; and exerts anti-tumor effects via ferroptosis/apoptosis and metastasis blockade, thereby elucidating its traditional functions of "promoting blood circulation and removing blood stasis" and "dissipating masses and resolving lumps" at the molecular level. Clinically, when combined with warfarin or aspirin, it enhances efficacy synergistically while maintaining a favorable safety profile.
S. miltiorrhiza and its active constituents exhibit promising therapeutic effects through synergistic cardiovascular protection, neuroprotection, and anticancer activities. This research supports the development of novel clinical drugs derived from S. miltiorrhiza while addressing gaps in understanding its pharmacological mechanisms.
This review aims to elucidate the synergistic effects of S. miltiorrhiza and its bioactive constituents across various stages of cardiovascular diseases, neurodegenerative disorders, and cancer progression by summarizing the key targets and signaling pathways involved.
A comprehensive search was conducted across PubMed, Web of Science, EMBASE, the Cochrane Library, SpringerLink, Elsevier, and the China National Knowledge Infrastructure (CNKI). The keywords employed included "cardiovascular protection", "neuroprotection", "anti-cancer", "Salvia miltiorrhiza", "active ingredients", and "pharmacological mechanisms". Relevant studies published from 2010 to 2025 were systematically screened, extracted, and analyzed to elucidate the mechanistic pathways and translational potential of S. miltiorrhiza and its active constituents in various therapeutic contexts. Furthermore, authoritative materials, monographs, and classical texts published prior to 2010 were referenced to provide historical and ethnopharmacological context.
S. miltiorrhiza's active constituents exert synergistic, multi-target regulation of oxidative stress, inflammation, and cell death across cardiovascular, cerebrovascular, and oncological diseases, embodying the modern connotation of "treating different diseases with the same method." Pharmacokinetically, lipophilic constituents exhibit extensive tissue distribution but low oral bioavailability, whereas hydrophilic constituents show the opposite; their combination may optimize in vivo exposure and therapeutic effects. Mechanistically, S. miltiorrhiza combats atherosclerosis by modulating cholesterol metabolism, inflammation, and vascular function; ameliorates neuronal damage by interfering with Aβ metabolism and neurotransmitter signaling; and exerts anti-tumor effects via ferroptosis/apoptosis and metastasis blockade, thereby elucidating its traditional functions of "promoting blood circulation and removing blood stasis" and "dissipating masses and resolving lumps" at the molecular level. Clinically, when combined with warfarin or aspirin, it enhances efficacy synergistically while maintaining a favorable safety profile.
S. miltiorrhiza and its active constituents exhibit promising therapeutic effects through synergistic cardiovascular protection, neuroprotection, and anticancer activities. This research supports the development of novel clinical drugs derived from S. miltiorrhiza while addressing gaps in understanding its pharmacological mechanisms.
Authors
Wang Wang, Wu Wu, Lai Lai, Li Li, Huang Huang, Wang Wang, Zhou Zhou, Xiao Xiao, Meng Meng, Qian Qian
View on Pubmed